Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

ClinicalTrials.gov ID: NCT00676052

Public ClinicalTrials.gov record NCT00676052. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 12:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the efficacy and safety of GSK233705B compared with placebo in subjects with COPD.

Study identification

NCT ID
NCT00676052
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
576 participants

Conditions and interventions

Eligibility (public fields only)

Age range
40 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 15, 2008
Primary completion
Dec 21, 2008
Completion
Dec 21, 2008
Last update posted
Oct 8, 2017

2008

United States locations

U.S. sites
25
U.S. states
12
U.S. cities
24
Facility City State ZIP Site status
GSK Investigational Site Jasper Alabama 35501
GSK Investigational Site Glendale Arizona 85306
GSK Investigational Site Fountain Valley California 92708
GSK Investigational Site Fullerton California 92835
GSK Investigational Site Los Angeles California 90048
GSK Investigational Site Los Angeles California 90095
GSK Investigational Site Riverside California 92506
GSK Investigational Site Roseville California 95661
GSK Investigational Site San Diego California 92103-8415
GSK Investigational Site Brandon Florida 33511
GSK Investigational Site Panama City Florida 32405
GSK Investigational Site South Miami Florida 33143
GSK Investigational Site Coeur d'Alene Idaho 83814
GSK Investigational Site Madisonville Kentucky 42431
GSK Investigational Site Lafayette Louisiana 70503
GSK Investigational Site Sunset Louisiana 70584
GSK Investigational Site Saint Charles Missouri 63301
GSK Investigational Site Charlotte North Carolina 28207
GSK Investigational Site Charleston South Carolina 29406-7108
GSK Investigational Site Greenville South Carolina 29615
GSK Investigational Site Spartanburg South Carolina 29303
GSK Investigational Site Union South Carolina 29379
GSK Investigational Site Houston Texas 77030
GSK Investigational Site Abingdon Virginia 24210
GSK Investigational Site Richmond Virginia 23229

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 63 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00676052, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 8, 2017 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00676052 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →